Comparing the current results to its competitors, Inhibrx Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.05 %, recorded in the same quarter.
Inhibrx Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 188.44 %
Inhibrx Biosciences Inc 's Comment on Competition and Industry Peers
The company operates within the biopharmaceutical industry, which is marked by rapid technological advancements and robust intellectual property protections. It competes with major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and research organizations. Competitors developing novel therapeutics based on single-domain antibodies (sdAb) or alternative scaffold product candidates include Crescendo Biologics Ltd., Molecular Partners AG, Precirix NV, Affibody Medical AB, Numab Therapeutics AG, GT Biopharma, Inc., and Sanofi. Additionally, companies engaged in antibody drug discovery such as Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., Numab Therapeutics AG, Amgen, Inc., Xencor, Inc., and Zymeworks Inc. compete in identifying novel therapeutic antibody targets. The company also faces competition from firms developing therapeutics for autoimmune diseases, including Sanofi, Amgen, Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Merck & Co., Inc., Novartis AG, Candid Therapeutics, Inc., Hinge Bio, Inc., and Apogee Therapeutics, Inc. Key competitive factors in the industry include efficacy, safety, convenience, diagnostic effectiveness, pricing, and reimbursement levels.
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
X4 Pharmaceuticals Inc is a biopharmaceutical company focused on the research and development of innovative treatments for rare diseases, particularly those involving the immune system and rare genetic disorders. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials, and ultimately bringing these therapies to market to improve patient outcomes.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.
Sources:
Inhibrx Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inhibrx Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
